Related Experiment Video
Updated: Jul 8, 2026

A Mouse Model of Single and Repetitive Mild Traumatic Brain Injury
Published on: June 20, 2017
Mild TBI Results in a Long-Term Decrease in Circulating Phospholipids in a Mouse Model of Injury
Tanja Emmerich1,2,3, Laila Abdullah4,5,6, Joseph Ojo4,5
1The Roskamp Institute, 2040 Whitfield Avenue, Sarasota, FL, 34243, USA. temmerich@roskampinstitute.net.
Abstract:
Neurophysiological and neurological dysfunction is usually experienced for a short period of time in patients with mild traumatic brain injury (mTBI). However, around 15 % of patients exhibit symptoms months after TBI. Phospholipid (PL) changes have been observed in plasma from mTBI patients at chronic stages, suggesting a role in TBI pathology. We examined long-term plasma phospholipid profiles in a mouse model of mTBI to determine their translational value in reproducing PL changes observed in mTBI patients. Plasma samples were collected at an acute timepoint (24 h post-injury) and at several chronic stages (3, 6, 12 and 24 months post-injury) from injured mice and sham controls. Phospholipids were identified and quantified using liquid chromatography/mass spectrometry analysis. In accordance with human data, we observed significantly lower levels of several major PL classes in mTBI mice compared to controls at chronic timepoints. Saturated, monounsaturated and polyunsaturated fatty acids (PUFAs) were differently regulated over time. As PUFA levels were decreased at 3 months, we measured levels of malondialdehyde to assess lipid peroxidation, which we found to be elevated at this timepoint. Ether-containing PE species were elevated at 24 h post-injury and decreased relative to controls at chronic stages. Arachidonic acid and docosahexaenoic acid-containing species were significantly decreased within all PL classes at the chronic stages. Our findings are similar to changes in PL levels observed in human mTBI subjects. Chronic TBI biomarkers have received little attention, even though disabilities at this stage can be of major importance. Our study provides information on biochemical abnormalities that persist long after the initial injury; these abnormalities may provide useful insight into the continuing pathogenesis and serve as diagnostic biomarkers.
Insights
Mild traumatic brain injury (mTBI) can cause long-term phospholipid changes in mice, mirroring human patient data. These chronic alterations may serve as diagnostic biomarkers for persistent TBI pathology.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Mild traumatic brain injury (mTBI) often leads to short-term dysfunction, but ~15% of patients experience chronic symptoms.
- Phospholipid (PL) alterations in plasma suggest a role in chronic TBI pathology.
- Understanding long-term biochemical changes is crucial for diagnosing and managing persistent TBI disabilities.
Purpose of the Study:
- To investigate long-term plasma phospholipid profiles in a mouse model of mTBI.
- To assess the translational value of mouse mTBI models for human PL changes.
- To identify potential chronic TBI biomarkers.
Main Methods:
- Mice were subjected to mTBI or sham procedures, with plasma collected at acute (24h) and chronic (3, 6, 12, 24 months) timepoints.
- Liquid chromatography/mass spectrometry was used to identify and quantify phospholipids.
- Malondialdehyde levels were measured to assess lipid peroxidation.
Main Results:
- Chronic mTBI mice showed significantly lower levels of major PL classes compared to controls.
- Polyunsaturated fatty acid (PUFA) levels decreased at 3 months, coinciding with elevated lipid peroxidation.
- Ether-containing phosphatidylethanolamine (PE) species were elevated acutely but decreased chronically; arachidonic and docosahexaenoic acid species were reduced long-term.
Conclusions:
- Plasma PL profiles in chronic mTBI mice resemble those observed in human patients.
- Persistent biochemical abnormalities after TBI may offer insights into ongoing pathogenesis.
- Identified long-term PL changes could serve as diagnostic biomarkers for chronic TBI.

